ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2013
Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates.
Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.PloS one · 2015Trial
- ProSAAS neuropeptides and receptors GPR171 and GPR83: Potential therapeutic applications for pain, anxiety, and body weight regulation.The Journal of pharmacology and experimental therapeutics · 2025Review
- Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry.Molecular & cellular proteomics : MCP · 2024Review
- Article
- CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum.International journal of Alzheimer's disease · 2023Article
- Sequestration of TDP-43ACS chemical neuroscience · 2022Article
- A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.Clinical proteomics · 2020Review
- Secreted Chaperones in Neurodegeneration.Frontiers in aging neuroscience · 2020Review
- Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.Journal of molecular neuroscience : MN · 2019Article
- Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias.Proteomes · 2018Review
- Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins.Behavioural brain research · 2018Review
- Proteomics Applications in Health: Biomarker and Drug Discovery and Food Industry.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.Biotechnology and bioengineering · 2017Article
- Article
- Construction and characterization of the Korean whole saliva proteome to determine ethnic differences in human saliva proteome.PloS one · 2017Article
- A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.Translational psychiatry · 2016Article
- Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease.Archives of pharmacal research · 2016Article
- Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?Molecular & cellular proteomics : MCP · 2016Review
- Chaperones in Neurodegeneration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Review
- A Proteomic Analysis of Individual and Gender Variations in Normal Human Urine and Cerebrospinal Fluid Using iTRAQ Quantification.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is significant interest in the development of methods to validate novel biomarkers for Alzheimer's disease (AD) diagnosis. Previously, a proteomic panel of cerebrospinal fluid (CSF) biomarker candidates that differentiated AD and non-AD CSF with accuracy higher than 90% was found; information about these CSF proteins can be used to develop multiple reaction monitoring (MRM) based analytical assays, which offer the possibility of quantifying protein expression level changes in samples, as well as, validation among multiple laboratories. Here we report an MRM assay that demonstrates good linearity (average R(2)=0.969) and reproducibility (average coefficient of variance of 6.93%) for the proposed AD CSF biomarkers. MRM quantification results of Aβ1-40, Aβ1-42, retinol-binding protein and cystatin C correlated well with those from ELISA (average R(2)=0.974). Analysis shows that 12 out of 16 selected targets exhibit the same trend in protein expression as that in literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.